---
id: tmp-smx-mechanism-spectrum_175
category: antimicrobials
tags: [tmp-smx, trimethoprim, sulfamethoxazole, mechanism, spectrum, folate]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## TMP-SMX - Mechanism & Spectrum

**Q:** What is the mechanism of action of TMP-SMX and what is its antimicrobial spectrum including key organisms it covers?

**A:**

## MECHANISM OF ACTION

**Sequential Blockade of Folate Synthesis (Synergistic Combination):**

**Mnemonic: "TWO-STEP-FOLATE-BLOCK"**

**Sulfamethoxazole (SMX):**
- **Step 1:** **PABA analog** → competes for **dihydropteroate synthase**
- **Blocks:** Para-aminobenzoic acid (PABA) → **Dihydrofolic acid**
- **Bacteriostatic alone**

**Trimethoprim (TMP):**
- **Step 2:** **Inhibits dihydrofolate reductase (DHFR)**
- **Blocks:** Dihydrofolic acid → **Tetrahydrofolic acid** (active form)
- **Bacteriostatic alone**

**Combined Effect:**
- **Sequential blockade** → **bactericidal** (synergy)
- **Ratio:** 1:5 (TMP:SMX in serum) or 1:20 (in formulation)

**Key Point:** **TMP-SMX = sequential folate synthesis blockade** → synergistic bactericidal effect

---

## ANTIMICROBIAL SPECTRUM

**Mnemonic: "MRSA-STENOTROPHOMONAS-PNEUMOCYSTIS-NOCARDIA"**

### **GRAM-POSITIVE COVERAGE:**

**Excellent:**
- ***MRSA*** (community-acquired - excellent oral option)
- ***Staphylococcus aureus*** (MSSA)
- **Streptococcus pneumoniae** (increasing resistance)
- **Listeria monocytogenes** (alternative to ampicillin)

**Poor/No Activity:**
- **Group A Streptococcus** (GAS) - NOT reliable
- **Enterococcus** - intrinsically resistant

**Key Point:** **MRSA = excellent coverage** (first-line oral for CA-MRSA skin infections)

---

### **GRAM-NEGATIVE COVERAGE:**

**Excellent:**
- ***Stenotrophomonas maltophilia*** (ONLY reliable drug - first-line)
- **Most Enterobacterales** (E. coli, Klebsiella, Proteus)
- **Haemophilus influenzae**
- **Moraxella catarrhalis**
- ***Burkholderia cepacia*** (cystic fibrosis)

**No Activity:**
- ***Pseudomonas aeruginosa*** (intrinsically resistant)
- **Anaerobes** (no activity)

**Key Point:** **Stenotrophomonas = ONLY reliable drug** (first-line therapy)

---

### **ATYPICAL BACTERIA:**

**Nocardia Species:**
- ***Nocardia asteroides*** (first-line - 90% susceptible)
- **TMP-SMX = drug of choice** for nocardiosis (CNS, pulmonary, disseminated)

**Key Point:** **Nocardia = first-line TMP-SMX** (6-12 months therapy)

---

### **FUNGI:**

***Pneumocystis jirovecii***:
- **Drug of choice** for PCP treatment AND prophylaxis
- **Mechanism:** Inhibits dihydrofolate reductase in *Pneumocystis*

**Key Point:** **PCP = first-line TMP-SMX** (treatment + prophylaxis)

---

### **PARASITES:**

**Excellent:**
- ***Toxoplasma gondii*** (first-line with leucovorin)
- ***Cyclospora cayetanensis*** (first-line)
- ***Cystoisospora belli*** (Isospora - first-line)

**Key Point:** **Toxoplasma = first-line TMP-SMX + leucovorin**

---

## RESISTANCE MECHANISMS

**Mnemonic: "ALTERED-ENZYMES-EFFLUX-OVERPRODUCTION"**

**Mechanisms:**
1. **Altered DHFR enzyme** (TMP resistance)
2. **Altered dihydropteroate synthase** (SMX resistance)
3. **Increased PABA production** (overcomes SMX inhibition)
4. **Efflux pumps** (pump drug out)
5. **Thymidine-rich environment** (bypasses need for folate synthesis)

**Key Point:** **Resistance = altered enzymes or increased PABA production**

---

## CLINICAL USES

**Mnemonic: "MRSA-UTI-PCP-NOCARDIA-STENOTROPHOMONAS"**

**Top 5 Uses:**
1. **CA-MRSA skin infections** (first-line oral)
2. **Urinary tract infections** (E. coli, Proteus - BUT increasing resistance)
3. **PCP prophylaxis** (CD4 <200) and treatment (first-line)
4. **Nocardiosis** (first-line - 6-12 months)
5. **Stenotrophomonas maltophilia** (ONLY reliable drug)

**Other Uses:**
- **Toxoplasmosis** (CNS, disseminated + leucovorin)
- **Cyclospora/Isospora** diarrhea (first-line)
- **Listeria meningitis** (alternative to ampicillin)
- **Burkholderia cepacia** (cystic fibrosis)
- **Whipple disease** (after ceftriaxone induction)

**Key Point:** **5 key uses: MRSA, UTI, PCP, Nocardia, Stenotrophomonas**

---

## DOSING

**Treatment Doses (Based on TMP Component):**

**Oral:**
- **Standard:** 1-2 DS tablets (160mg TMP/800mg SMX) PO BID
- **High-dose (PCP, Nocardia):** 5mg/kg TMP PO TID (15mg/kg/day)

**IV:**
- **Standard:** 5mg/kg TMP IV Q8H (15mg/kg/day)
- **PCP treatment:** 5mg/kg TMP IV Q6-8H (15-20mg/kg/day)

**PCP Prophylaxis:**
- **Standard:** 1 DS tablet (160/800mg) PO daily OR 3x/week
- **Alternative:** 1 SS tablet (80/400mg) PO daily

**Key Point:** **Dosing based on TMP component** (5mg/kg TMP for serious infections)

---

## PENETRATION

**Excellent Tissue Penetration:**
- **CNS:** 40-50% CSF penetration (excellent for CNS infections)
- **Lung:** High concentrations (excellent for PCP, Nocardia)
- **Prostate:** Excellent penetration (prostatitis coverage)
- **Bone:** Good penetration (osteomyelitis - though NOT first-line)

**Key Point:** **Excellent CNS, lung, prostate penetration**

---

**Clinical Pearls:**
- **TMP-SMX = sequential folate blockade** → synergistic bactericidal
- **MRSA = excellent coverage** (first-line oral for CA-MRSA skin infections)
- **Stenotrophomonas = ONLY reliable drug** (first-line therapy)
- **Nocardia = first-line TMP-SMX** (6-12 months therapy)
- **PCP = first-line TMP-SMX** (treatment + prophylaxis, CD4 <200)
- **Toxoplasma = first-line TMP-SMX + leucovorin**
- **No activity:** Pseudomonas, anaerobes, Enterococcus
- **Dosing based on TMP component** (5mg/kg TMP for serious infections)
- **Excellent CNS, lung, prostate penetration**

**Media:**

**Additional Resources:**
- **Sanford Guide:** TMP-SMX spectrum
- **IDSA Guidelines:** PCP prophylaxis and treatment
- **IBCC:** https://emcrit.org/ibcc/tmp-smx/

**Sources:** [Sanford Guide], [IDSA PCP Guidelines], [IBCC TMP-SMX]
